Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Voyager Therapeutics (VYGR) EBT: 2014-2024

Historic EBT for Voyager Therapeutics (VYGR) over the last 11 years, with Dec 2024 value amounting to -$64.3 million.

  • Voyager Therapeutics' EBT fell 208.95% to -$27.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$126.1 million, marking a year-over-year decrease of 570.68%. This contributed to the annual value of -$64.3 million for FY2024, which is 148.11% down from last year.
  • As of FY2024, Voyager Therapeutics' EBT stood at -$64.3 million, which was down 148.11% from $133.7 million recorded in FY2023.
  • Voyager Therapeutics' 5-year EBT high stood at $133.7 million for FY2023, and its period low was -$71.2 million during FY2021.
  • For the 3-year period, Voyager Therapeutics' EBT averaged around $7.7 million, with its median value being -$46.4 million (2022).
  • As far as peak fluctuations go, Voyager Therapeutics' EBT crashed by 293.78% in 2021, and later spiked by 388.28% in 2023.
  • Yearly analysis of 5 years shows Voyager Therapeutics' EBT stood at $36.7 million in 2020, then crashed by 293.78% to -$71.2 million in 2021, then spiked by 34.84% to -$46.4 million in 2022, then soared by 388.28% to $133.7 million in 2023, then slumped by 148.11% to -$64.3 million in 2024.